Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.

Arnon R, Aharoni R.

Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14593-8. Epub 2004 Sep 15.

2.

Glatiramer acetate: mechanisms of action in multiple sclerosis.

Ziemssen T, Schrempf W.

Int Rev Neurobiol. 2007;79:537-70. Review.

PMID:
17531858
3.

Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.

Aharoni R.

J Autoimmun. 2014 Nov;54:81-92. doi: 10.1016/j.jaut.2014.05.005. Epub 2014 Jun 14. Review.

PMID:
24934599
4.

Glatiramer acetate: mechanisms of action in multiple sclerosis.

Schrempf W, Ziemssen T.

Autoimmun Rev. 2007 Aug;6(7):469-75. Epub 2007 Mar 6. Review.

PMID:
17643935
5.

Immunomodulation by the copolymer glatiramer acetate.

Arnon R, Sela M.

J Mol Recognit. 2003 Nov-Dec;16(6):412-21. Review.

PMID:
14732933
6.

Recent insights into the mechanism of action of glatiramer acetate.

Kala M, Miravalle A, Vollmer T.

J Neuroimmunol. 2011 Jun;235(1-2):9-17. doi: 10.1016/j.jneuroim.2011.01.009. Epub 2011 Mar 13. Review.

PMID:
21402415
7.
8.

Glatiramer acetate (Copaxone) therapy for multiple sclerosis.

Dhib-Jalbut S.

Pharmacol Ther. 2003 May;98(2):245-55. Review.

PMID:
12725872
9.

The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.

Aharoni R.

Autoimmun Rev. 2013 Mar;12(5):543-53. doi: 10.1016/j.autrev.2012.09.005. Epub 2012 Oct 7. Review.

PMID:
23051633
10.

Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate.

Arnon R, Aharoni R.

J Neural Transm (Vienna). 2009 Nov;116(11):1443-9. doi: 10.1007/s00702-009-0272-3. Epub 2009 Aug 11. Review.

PMID:
19669693
11.

Copolymer 1: from basic research to clinical application.

Teitelbaum D, Arnon R, Sela M.

Cell Mol Life Sci. 1997 Jan;53(1):24-8. Review.

PMID:
9117994
12.

Therapeutic vaccines in autoimmunity.

Sela M, Mozes E.

Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14586-92. Epub 2004 Aug 12. Review.

13.

Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.

Weber MS, Hohlfeld R, Zamvil SS.

Neurotherapeutics. 2007 Oct;4(4):647-53. Review.

PMID:
17920545
14.

New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

Arnon R, Sela M, Teitelbaum D.

J Neurol. 1996 Apr;243(4 Suppl 1):S8-13. Review.

PMID:
8965119
15.

The use of glatiramer acetate in the treatment of multiple sclerosis.

Wolinsky JS.

Adv Neurol. 2006;98:273-92. Review.

PMID:
16400839
16.

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.

Dhib-Jalbut S.

Neurology. 2002 Apr 23;58(8 Suppl 4):S3-9. Review.

PMID:
11971121
17.

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.

Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R.

Lancet Neurol. 2005 Sep;4(9):567-75. Review.

PMID:
16109363
18.

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS.

CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000. Review.

19.

Glatiramer acetate in multiple sclerosis: a review.

Ruggieri M, Avolio C, Livrea P, Trojano M.

CNS Drug Rev. 2007 Summer;13(2):178-91. Review.

20.

Specific vaccines against autoimmune diseases.

Sela M.

C R Acad Sci III. 1999 Nov;322(11):933-8. Review.

PMID:
10646086

Supplemental Content

Support Center